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18F-2-deoxy-2-fluoro-D-glucose (18F-FDG) is useful as a tumor-detecting agent in 
clinical positron emission tomography (PET) studies1).  However, 18F-FDG accumulates 
highly not only in tumors but also in inflamed tissues2).  This nonspecific accumulation of 
18F-FDG leads to false-positive results and reduces the diagnostic accuracy3). 
In tumor cells, amino acid metabolism is enhanced and amino acid transport and the 
rate of protein synthesis increase4).  On the other hand, inflammatory cells did not take 
amino acids much compared with 18F-FDG5,6).  These properties suggest the specificity in 
tumor imaging.  Various amino acids have been labeled for the tumor detection and 
investigated for their clinical application in oncology7). 
Recently, the synthesis of O-[18F]fluoromethyl-L-tyrosine (18F-FMT), has been 
reported as a new tumor-detecting agent by Iwata et al.8).  The 18F-FMT preparation was 
simple with high radiochemical yields and consequently suitable for routine production. 
The aim of this study was to evaluate the potency of 18F-FMT for the differentiation 
between tumor and inflammation using animal models with experimentally induced 
inflammation and implanted tumor. 
 
Materials and methods 
The animal study was carried out according to the protocol approved by the Animal 
Care Committees of Cyclotron and Radioisotope Center, Tohoku University.  
The methods of 18F-FMT labeling with 18F were reported elsewhere8). 
Male Donryu rats weighing 150 to 180 g (Japan SLC, Japan) were used.  They 
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were fed food and water ad lib.  Tumor cell suspension of ascites hepatoma, AH109A 
(Cell Resource Center for Biomedical Research, Tohoku University, Japan), was inoculated 
subcutaneously into the right thigh of the rats 7 days before the experiment.  Ten 
microliters of turpentine oil (Wako Pure Chemical Industries Co., Ltd., Japan) was injected 
subcutaneously into the rats’ back twice in different positions 12 and 4 days respectively 
before the experiment to induce inflammation foci.  These inflammation foci were 
assumed to represent chronic and acute inflammations, respectively.   
Rats were injected intravenously with 1.85 MBq of 18F-FMT via the tail vein, and 
sacrificed at five time points (5, 10, 30, 60 and 120 min after injection).  Blood and the 
tissues of interest (tumor, acute inflammation, chronic inflammation, brain, heart, pancreas, 
liver, kidney, small intestine, muscle and bone) were partially or wholly removed 
immediately.  The samples were weighed and 18F radioactivity was measured by a gamma 
counter (PerkinElmer, Inc., USA).  The amount of radioactivity was expressed as a 
percentage of the injected dose per gram of tissue (%ID/g). 
One-way ANOVA with Scheffé’s F correction was used to analyze all the results. 
Statistical significance was considered at P < 0.05. 
 
Results and discussion 
Table 1 shows the results of biodistribution studies with 18F-FMT in tumor and 
inflammation bearing rats.  Tissue radioactivities, in general, showed a steady decline in 
the course of the experiment, while tumor, the pancreas and the bone showed either 
retention or build-up patterns.  18F-FMT accumulations in tumors at 30 and 60 min after 
injection were significantly higher than those of the other tissues (P < 0.01), except for the 
pancreas.  The peak uptake time in the tumor was found to be around 60 min after 
injection, and the %ID/g in tumor at this time point was 3.2 times higher than in the other 
tissues, except for the pancreas.  The accumulations of 18F-FMT in acute and chronic 
inflammations were similar and showed no statistical difference from the background 
tissues at all time points. 
In conclusion, although this study is still preliminary, 18F-FMT seems promising 
tracer for the differentiation between tumors and inflammation with higher specificity to 
tumors.  The simplicity in radiolabeling supports 18F-FMT as a potential amino acid tracer 
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